Requirement for sphingosine kinase 1 in mediating phase 1 of the hypotensive response to anandamide in the anaesthetised mouse

Fiona H. Greig, Katrin Nader, Margaret D. Ballantyne, Zeshan H. Kazi, Husam Alganga, Marie-Ann Ewart, Karolina E. Zaborska, Bracy Fertig, Nigel J. Pyne, Susan Pyne, Simon Kennedy

Research output: Contribution to journalArticle

Abstract

In the isolated rat carotid artery, the endocannabinoid anandamide induces endothelium-dependent relaxation via activation of the enzyme sphingosine kinase (SK). This generates sphingosine 1-phosphate (S1P) which can be released from the cell and activates S1P receptors on the endothelium. In anaesthetised mice, anandamide has a well-characterised triphasic effect on blood pressure but the contribution of SK and S1P receptors in mediating changes in blood pressure has never been studied. Therefore, we assessed this in the current study. The peak hypotensive response to 1 and 10 mg/kg anandamide was measured in control C57BL/6 mice and in mice pretreated with selective inhibitors of SK1 (BML-258, also known as SK1-I) or SK2 ((R)-FTY720 methylether (ROMe), a dual SK1/2 inhibitor (SKi) or an S1P1 receptor antagonist (W146). Vasodilator responses to S1P were also studied in isolated mouse aortic rings.

The hypotensive response to anandamide was significantly attenuated by BML-258 but not by ROMe. Antagonising S1P1 receptors with W146 completely blocked the fall in systolic but not diastolic blood pressure in response to anandamide. S1P induced vasodilation in denuded aortic rings was blocked by W146 but caused no vasodilation in endothelium-intact rings.

This study provides evidence that the SK1/S1P regulatory-axis is necessary for the rapid hypotension induced by anandamide. Generation of S1P in response to anandamide likely activates S1P1 to reduce total peripheral resistance and lower mean arterial pressure. These findings have important implications in our understanding of the hypotensive and cardiovascular actions of cannabinoids.
LanguageEnglish
Pages1-9
Number of pages9
JournalEuropean Journal of Pharmacology
Volume842
Early online date23 Oct 2018
DOIs
StatePublished - 5 Jan 2019

Fingerprint

Lysosphingolipid Receptors
Blood Pressure
Endothelium
Vasodilation
Controlled Hypotension
Endocannabinoids
Enzyme Activation
Cannabinoids
sphingosine kinase
sphingosine 1-phosphate
anandamide
Vasodilator Agents
Inbred C57BL Mouse
Carotid Arteries
Vascular Resistance
Arterial Pressure
N-methyl-5-(4'-pentylphenyl)-2-aminopent-4-ene-1,3-diol
Fingolimod Hydrochloride

Keywords

  • sphingosine kinase
  • sphingosine-1-phosphate
  • hypotension
  • anandamide
  • mouse

Cite this

Greig, F. H., Nader, K., Ballantyne, M. D., Kazi, Z. H., Alganga, H., Ewart, M-A., ... Kennedy, S. (2019). Requirement for sphingosine kinase 1 in mediating phase 1 of the hypotensive response to anandamide in the anaesthetised mouse. European Journal of Pharmacology, 842, 1-9. DOI: 10.1016/j.ejphar.2018.10.027
Greig, Fiona H. ; Nader, Katrin ; Ballantyne, Margaret D. ; Kazi, Zeshan H. ; Alganga, Husam ; Ewart, Marie-Ann ; Zaborska, Karolina E. ; Fertig, Bracy ; Pyne, Nigel J. ; Pyne, Susan ; Kennedy, Simon. / Requirement for sphingosine kinase 1 in mediating phase 1 of the hypotensive response to anandamide in the anaesthetised mouse. In: European Journal of Pharmacology. 2019 ; Vol. 842. pp. 1-9
@article{5b0abaa6d5594180ae49dd59d313902c,
title = "Requirement for sphingosine kinase 1 in mediating phase 1 of the hypotensive response to anandamide in the anaesthetised mouse",
abstract = "In the isolated rat carotid artery, the endocannabinoid anandamide induces endothelium-dependent relaxation via activation of the enzyme sphingosine kinase (SK). This generates sphingosine 1-phosphate (S1P) which can be released from the cell and activates S1P receptors on the endothelium. In anaesthetised mice, anandamide has a well-characterised triphasic effect on blood pressure but the contribution of SK and S1P receptors in mediating changes in blood pressure has never been studied. Therefore, we assessed this in the current study. The peak hypotensive response to 1 and 10 mg/kg anandamide was measured in control C57BL/6 mice and in mice pretreated with selective inhibitors of SK1 (BML-258, also known as SK1-I) or SK2 ((R)-FTY720 methylether (ROMe), a dual SK1/2 inhibitor (SKi) or an S1P1 receptor antagonist (W146). Vasodilator responses to S1P were also studied in isolated mouse aortic rings.The hypotensive response to anandamide was significantly attenuated by BML-258 but not by ROMe. Antagonising S1P1 receptors with W146 completely blocked the fall in systolic but not diastolic blood pressure in response to anandamide. S1P induced vasodilation in denuded aortic rings was blocked by W146 but caused no vasodilation in endothelium-intact rings.This study provides evidence that the SK1/S1P regulatory-axis is necessary for the rapid hypotension induced by anandamide. Generation of S1P in response to anandamide likely activates S1P1 to reduce total peripheral resistance and lower mean arterial pressure. These findings have important implications in our understanding of the hypotensive and cardiovascular actions of cannabinoids.",
keywords = "sphingosine kinase, sphingosine-1-phosphate, hypotension, anandamide, mouse",
author = "Greig, {Fiona H.} and Katrin Nader and Ballantyne, {Margaret D.} and Kazi, {Zeshan H.} and Husam Alganga and Marie-Ann Ewart and Zaborska, {Karolina E.} and Bracy Fertig and Pyne, {Nigel J.} and Susan Pyne and Simon Kennedy",
year = "2019",
month = "1",
day = "5",
doi = "10.1016/j.ejphar.2018.10.027",
language = "English",
volume = "842",
pages = "1--9",
journal = "European Journal of Pharmacology",
issn = "0014-2999",

}

Greig, FH, Nader, K, Ballantyne, MD, Kazi, ZH, Alganga, H, Ewart, M-A, Zaborska, KE, Fertig, B, Pyne, NJ, Pyne, S & Kennedy, S 2019, 'Requirement for sphingosine kinase 1 in mediating phase 1 of the hypotensive response to anandamide in the anaesthetised mouse' European Journal of Pharmacology, vol. 842, pp. 1-9. DOI: 10.1016/j.ejphar.2018.10.027

Requirement for sphingosine kinase 1 in mediating phase 1 of the hypotensive response to anandamide in the anaesthetised mouse. / Greig, Fiona H.; Nader, Katrin; Ballantyne, Margaret D.; Kazi, Zeshan H.; Alganga, Husam; Ewart, Marie-Ann; Zaborska, Karolina E.; Fertig, Bracy; Pyne, Nigel J.; Pyne, Susan; Kennedy, Simon.

In: European Journal of Pharmacology, Vol. 842, 05.01.2019, p. 1-9.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Requirement for sphingosine kinase 1 in mediating phase 1 of the hypotensive response to anandamide in the anaesthetised mouse

AU - Greig,Fiona H.

AU - Nader,Katrin

AU - Ballantyne,Margaret D.

AU - Kazi,Zeshan H.

AU - Alganga,Husam

AU - Ewart,Marie-Ann

AU - Zaborska,Karolina E.

AU - Fertig,Bracy

AU - Pyne,Nigel J.

AU - Pyne,Susan

AU - Kennedy,Simon

PY - 2019/1/5

Y1 - 2019/1/5

N2 - In the isolated rat carotid artery, the endocannabinoid anandamide induces endothelium-dependent relaxation via activation of the enzyme sphingosine kinase (SK). This generates sphingosine 1-phosphate (S1P) which can be released from the cell and activates S1P receptors on the endothelium. In anaesthetised mice, anandamide has a well-characterised triphasic effect on blood pressure but the contribution of SK and S1P receptors in mediating changes in blood pressure has never been studied. Therefore, we assessed this in the current study. The peak hypotensive response to 1 and 10 mg/kg anandamide was measured in control C57BL/6 mice and in mice pretreated with selective inhibitors of SK1 (BML-258, also known as SK1-I) or SK2 ((R)-FTY720 methylether (ROMe), a dual SK1/2 inhibitor (SKi) or an S1P1 receptor antagonist (W146). Vasodilator responses to S1P were also studied in isolated mouse aortic rings.The hypotensive response to anandamide was significantly attenuated by BML-258 but not by ROMe. Antagonising S1P1 receptors with W146 completely blocked the fall in systolic but not diastolic blood pressure in response to anandamide. S1P induced vasodilation in denuded aortic rings was blocked by W146 but caused no vasodilation in endothelium-intact rings.This study provides evidence that the SK1/S1P regulatory-axis is necessary for the rapid hypotension induced by anandamide. Generation of S1P in response to anandamide likely activates S1P1 to reduce total peripheral resistance and lower mean arterial pressure. These findings have important implications in our understanding of the hypotensive and cardiovascular actions of cannabinoids.

AB - In the isolated rat carotid artery, the endocannabinoid anandamide induces endothelium-dependent relaxation via activation of the enzyme sphingosine kinase (SK). This generates sphingosine 1-phosphate (S1P) which can be released from the cell and activates S1P receptors on the endothelium. In anaesthetised mice, anandamide has a well-characterised triphasic effect on blood pressure but the contribution of SK and S1P receptors in mediating changes in blood pressure has never been studied. Therefore, we assessed this in the current study. The peak hypotensive response to 1 and 10 mg/kg anandamide was measured in control C57BL/6 mice and in mice pretreated with selective inhibitors of SK1 (BML-258, also known as SK1-I) or SK2 ((R)-FTY720 methylether (ROMe), a dual SK1/2 inhibitor (SKi) or an S1P1 receptor antagonist (W146). Vasodilator responses to S1P were also studied in isolated mouse aortic rings.The hypotensive response to anandamide was significantly attenuated by BML-258 but not by ROMe. Antagonising S1P1 receptors with W146 completely blocked the fall in systolic but not diastolic blood pressure in response to anandamide. S1P induced vasodilation in denuded aortic rings was blocked by W146 but caused no vasodilation in endothelium-intact rings.This study provides evidence that the SK1/S1P regulatory-axis is necessary for the rapid hypotension induced by anandamide. Generation of S1P in response to anandamide likely activates S1P1 to reduce total peripheral resistance and lower mean arterial pressure. These findings have important implications in our understanding of the hypotensive and cardiovascular actions of cannabinoids.

KW - sphingosine kinase

KW - sphingosine-1-phosphate

KW - hypotension

KW - anandamide

KW - mouse

UR - https://www.journals.elsevier.com/european-journal-of-pharmacology

U2 - 10.1016/j.ejphar.2018.10.027

DO - 10.1016/j.ejphar.2018.10.027

M3 - Article

VL - 842

SP - 1

EP - 9

JO - European Journal of Pharmacology

T2 - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -